Table 6 Summary of studies assessing cost burden and healthcare resource utilisation in patients with AoRRP
Study | Country | Year | Parameter | Value [cost year] |
|---|---|---|---|---|
Studies presenting cost data in patients with AoRRP | ||||
Harrison 2016 | UK | 2013–2014 | Total cost | £107,478 [2014] |
Operating theatre cost | £92,828 [2014] | |||
Chesson 2012 | US | 2010 | Annual medical costs | Baseline (range): $48 m (2–236 m) USD [2010] |
Derkay 1995 | US | 1993–1994 | Surgical procedures | $42 m USD [NR] |
Tam 2020 | US | 2011–2014 and 2008–2012 | Medical cost in the first 2 years after diagnosis for patients with newly diagnosed AoRRP | Approx. $5,000 USD [2015] (Medicaid patients) |
Approx. $11,000 USD [2015] (privately insured) | ||||
Miller 2017 | UK | 2005–2012 | Operating theatre cost | Mean: $12,382 USD [NR] |
Office procedure cost | Mean: $3,413 [NR] | |||
Studies presenting resource data in patients with AoRRP | ||||
Miller 2017 | UK | 2005–2012 | Number of surgeries In-office laser procedures per patient: | Mean (SD): 13.5 (19.1) Mean (SD): 4.2 (17.1) |
Derkay 1995 | US | 1993–1994 | Lifetime papilloma operations | 11–20 operations: 15% 21–40 operations: 5% 41–100 operations: 10% > 100 operations: 9% |
Nogueira 2020 | Brazil | 2008–2015 | Number of surgeries | HPV6 mean (SD): 3.4 (2.0) HPV11 mean (SD): 4.5 (3.5) |
Omland 2014 | Norway | 1987–2009 | Annual surgical treatment per year | Median: 1.2 |
Annual surgical treatment during first three years | Median: 2.3 | |||
Studies evaluating the impact of HPV vaccination on resource utilization in patients with AoRRP | ||||
Kin 2017 | Germany | NR | Incidence rate of surgeries | Pre-vaccination: 47.4/1000 patient months Post-vaccination: 6.7/1000 patient months p < 0.0001 |
Matsuzaki 2020 | Japan | 2012–2018 | Number of surgeries | Mean before combination therapy: 3.3 Mean after combination therapy: 1.6 |
Yiu 2019 | US | 2012–2017 | Number of surgeries | Pre-vaccination: 2.7 Post-vaccination: 0.8 p = 0.014 |